

Journal Pre-proof



Should Antipyretics be used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?

Mahyar Etminan, PharmD, MSc (Epi), Mohit Sodhi, MSc, MD Candidate, Saeed Ganjizadeh-Zavareh, MD, MHSC

PII: S0012-3692(21)00254-3

DOI: <https://doi.org/10.1016/j.chest.2021.01.080>

Reference: CHEST 4018

To appear in: *CHEST*

Received Date: 19 January 2021

Revised Date: 26 January 2021

Accepted Date: 29 January 2021

Please cite this article as: Etminan M, Sodhi M, Ganjizadeh-Zavareh S, Should Antipyretics be used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?, *CHEST* (2021), doi: <https://doi.org/10.1016/j.chest.2021.01.080>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2021 Published by Elsevier Inc under license from the American College of Chest Physicians.

Should Antipyretics be used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?

Mahyar Etminan PharmD, MSc (Epi)¹, Mohit Sodhi MSc, MD Candidate^{1,2}, Saeed Ganjizadeh-Zavareh MD, MHSC³

¹Department of Ophthalmology and Visual Sciences, Faculty of Medicine, University of British Columbia, Vancouver, Canada.

²MD Undergraduate Program, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.

³Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, Canada.

Corresponding Author:

Mahyar Etminan PharmD, MSc

Associate Professor of Ophthalmology and Visual Sciences | Faculty of Medicine

The University of British Columbia | The Eye Care Center

Room 323-2550 Willow Street, Vancouver BC, V5Z 3N9

Phone 604-875-4725 | Fax 604-875-4663

Email: etminanm@mail.ubc.ca

Text word count: 793

Key words: Antipyretics; Ibuprofen; Acetaminophen; COVID-19 Vaccines; Adverse Events; Immunogenicity

Funding: This study did not require any funding

Conflicts of interest: None of the authors have any conflicts of interest to disclose.

Introduction

The introduction of new vaccines against COVID-19 including those from BioNTech and Moderna, among others, will be pivotal for controlling the SARS-CoV-2 pandemic. The availability and administration of these vaccines will be a pivotal step in controlling the COVID-19 pandemic.

The BioNTech and Moderna vaccines are currently the only ones approved for use in North America. These two vaccines, like many others, might also be associated with self-limiting acute adverse reactions (ADRs). The overall rate of systemic ADRs, based on recently published phase three trial data^{1,2} is considered low. For example, in the trial that used the BioNTech vaccine (18,860 vaccine users vs. 18,846 nonusers) the overall ADR rates with the first dose was 0.9%¹. However, a considerable proportion of vaccine recipients still reported fatigue (59% vs 52%, vaccine vs placebo users) and headache (51% vs. 39% among older recipients). Similarly, more patients taking the Moderna vaccine reported any systemic reaction (79.6% vs. 36.6.0%). Specifically, more subjects experienced myalgia (58.0% vs. 12.3%), arthralgia (42.9 % vs. 10.7%) and fatigue (65.7% vs. 23.3) with the vaccine². Based on these data and given the availability of antipyretics as over the counter medications, it is expected that potentially millions around the world might be using them to control acute systemic ADRs related to the COVID-19 vaccine.

Relevance

Historically, antipyretics such as ibuprofen or acetaminophen have been used to control the acute phase adverse events secondary to different vaccines. However, some studies have suggested that taking antipyretics immediately before or shortly after receiving a vaccine might interfere with its immunogenicity³, while some have not⁴. A two-part landmark randomised trial evaluated the effect of acetaminophen taken prophylactically (immediately following vaccination) in infants³. In this study, antibody titers were significantly lowered in those taking acetaminophen prophylactically compared to controls. Moreover, some of the differences in these findings might be due to age as the potential immune modulating effects of antipyretics and their potential negative interaction with vaccines might differ in children and adults.

A number of regulatory bodies have made statements regarding use of antipyretics around the time of vaccination. In 2015, the World Health Organization stated that use of antipyretics is not recommended before or at the time of vaccination but approved in the days following vaccination, and the Centers for Disease Control and Prevention concurs with these recommendations⁵.

Mechanism

The mechanism of decreased circulating antibodies due to antipyretic administration post-vaccination is not well understood; however, a few potential mechanisms have been postulated. Antipyretics such as acetaminophen and ibuprofen can interfere with the communication between the innate and adaptive immune system in lymphatic tissue, which occurs within hours of antigen administration. Most of the research on this topic has been undertaken looking at the effect of antibody production with antipyretics using animal models which warrants more human data from vaccines that use different platforms (protein, live attenuated or mRNA-based vaccines).

To date, no study has specifically examined the effect antipyretics on the immunogenicity of the COVID-19 vaccines. A recent report from the ½ single-blind randomised trial of the AstraZeneca (adenovirus-vectored vaccine) does mention that prophylactic use of acetaminophen did not interfere with the vaccine's immunogenicity although no data were provided, and these results might not be applicable to other mRNA type vaccines. Furthermore, there was no data provided on the use of antipyretics in the Moderna² trial, while the Pfizer¹ trial only mentioned that the use of antipyretics was increased with increasing dose concentrations and dose number, but data on immunogenicity were not given.

Future Directions

A potential negative interaction between antipyretic use and COVID-19 vaccines might have important public health repercussions, as they potentially affect the efficacy of the vaccine directly by hindering the vaccine's immune response. Indirectly, concerns about this interaction can lead to low utilization of antipyretics and potentially lead to non-adherence to the second dose. Going forward, clinical trials need to urgently answer four questions: 1) Do either

ibuprofen and acetaminophen affect antibody response by COVID-19 vaccines, and if so, is there a difference in antibody titres between the two agents; 2) Does a potential interaction with antipyretics differ with different vaccine types (mRNA vs. non mRNA vaccines); 3) Does the timing of antipyretic administration (before vaccination or immediately after) affect antibody titres; 4) Does a possible negative interaction only affect antibody titres for the first dose, second dose or both?

Multiple COVID-19 vaccines translating to billions of doses will be transiting through the pipeline soon and many might use over the counter antipyretic medications to curb early adverse events from these vaccines. Existence of a potential negative interaction between these drugs and the vaccine will need to be examined promptly as use of these drugs, especially with respect to the timing of vaccine administration, might be critical and potentially affect vaccines' immunogenicity.

Funding: This study did not require any funding

Conflicts of interest: None of the authors have any conflicts of interest to disclose.

Author contributions:

Conceptualization: ME

Supervision: ME

Investigation: ME, MS

Methodology: ME, MS

Writing- original draft: ME, MS

Writing – review and editing: ME, MS, SGZ

REFERENCES

1. Polack, FP, Thoas SJ, Absalon KJ et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New Engl J. Med.* 383, 2603-2615 (2020).
2. Baden LR, El Sahly MH, Essink B et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine -2 - Preliminary Report. *New Engl J. Med.* (2020), doi:10.1056/NEJMoa2035389
3. Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic acetaminophen administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. *Lancet.* 2009;374(9698):1339-50.
4. Doedée AM, Boland GJ, Pennings JL, et al. Effects of prophylactic and therapeutic acetaminophen treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials. *PLoS One.* 2014;9(6):e98175.
5. CDC General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html> . Accessed December 2, 2020.

Abbreviation List

1. **mRNA** Messenger RNA
2. **ADR** Adverse Drug Reactions
3. **COVID-19** Corona Virus Disease 19

Journal Pre-proof